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Background: Although the combination of cyclophosphamide and rituximab has been utilized in case reports,
there are no previous reports of the long term outcome of SLE treated systematically with this regimen. We report
a pilot study to evaluate the efficacy of a systematically administered course of rituximab and cyclophosphamide
over an eighteen month period to provide sustained improvement in childhood onset systemic lupus
erythematosus (SLE).
Findings: Twelve patients with childhood onset lupus nephritis or corticosteroid resistant SLE received systematic
treatment with a combination of rituximab (750 mg/M2 up to 1 gram) and cyclophosphamide (750 mg/M2: no
patient exceeded 1.8 M2). Two administrations of rituximab and cyclophosphamide, two weeks apart, were
administered at the start of study, six months later, and eighteen months later. Clinical data were collected and
analyzed after sixty months of follow up. There was sustained improvement in all clinical parameters with a
dramatic reduction in both mean SLEDAI score (10.1 to 1 at one year and 0 at five years p<0.005) and mean daily
prednisone dosage (29.7 mg/day to 12.7 by one year and 7.0 mg/day at five years p<0.005), with sustained
improvement in mean C3 (55.5 mg/ml to 113 at one year and 107.5 at five years p<0.001) which was maintained
through sixty months of follow up. Serum immunoglobulin levels were transiently depressed but mean values were
within the normal range for both IgG and IgM at one and five years. Few complications were observed (two
episodes of febrile neutropenia during the first year of treatment were the only serious adverse events) and
patients routinely reported sustained wellbeing.
Conclusions: This pilot study demonstrates that a systematically administered course of rituximab and
cyclophosphamide over an eighteen month period provided sustained relief for patients with childhood onset SLE which
was maintained over a sixty month period, while minimizing the need for corticosteroids, without excessive toxicity.Findings
This study demonstrates the long term safety and efficacy
of a limited course of concurrent rituximab and cyclophos-
phamide administered in a systematic fashion to twelve
patients with five years of follow-up. This therapy allowed
both substantial reduction in the total dosage of cyclo-
phosphamide and eliminated the need for continued oral* Correspondence: goldscout@aol.com
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stated.therapy with corticosteroids in doses above 0.25 mg/kg/
day, while providing sustained clinical improvement. The
short term results of this therapy have previously been re-
ported in abstract form.
The care of patients with childhood onset SLE is com-
plicated by frequent noncompliance with the prescribed
medication regimen. This results in part from the ad-
verse effects of corticosteroids on appearance, but non-
compliance among lupus patients is common with many
medications [1]. Noncompliance has been documented
with hydroxychloroquine which requires only a single dailyl Ltd. This is an Open Access article distributed under the terms of the Creative
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nolate mofetil which requires multiple daily doses associ-
ated with gastrointestinal side effects [2,3]. Noncompliance
is strongly associated with an increased frequency of dis-
ease flares, increased morbidity, and poor outcome [4].
Multiple approaches to the problem of noncompliance
have been proposed. These include educational pro-
grams, electronic monitoring, and automated medication
reminders [5-7]. However, the optimal solution is a regi-
men that both maximizes the physician's ability to moni-
tor compliance and minimizes the patient's need for
continued therapy. In the past, intravenous cyclophos-
phamide has been a standard regimen for the treatment
of life-threatening active childhood onset SLE [8-11].
Compliance with intravenous cyclophosphamide is easily
monitored, but patients and physicians remain concerned
about the long term side effects [12,13]. The risks of infec-
tion, sterility, and malignancy, and other toxicities lead to
reluctance to accept this therapy.
Efforts to develop alternative regimens with similar or
better efficacy and safety than repeated intravenous cyclo-
phosphamide administration have focused on mycophe-
nolate mofetil [14] and biologic agents such as rituximab.
Although intravenous rituximab has been beneficial in
many case reports, it has lacked efficacy in controlled tri-
als [15,16]. While rituximab targets only CD20 positive B
cells, cyclophosphamide is an alkylating agent which tar-
gets all rapidly dividing cell types [17].
Methods
Patients with childhood onset SLE complicated by active
diffuse proliferative glomerulonephritis ( DPGN), or who
failed to attain adequate disease control to allow appro-
priate reduction in the corticosteroid dosage during a
minimum three month trial were offered the opportun-
ity to participate. Appropriate reduction in corticoster-
oid therapy was defined as a reduction in the daily dose
of prednisone or equivalent to ≤ 0.25 mg/kg/day. Additional
medications such as hydroxychloroquine or angiotensin in-
hibitors were added or withdrawn at the discretion of the
attending physician. Prior therapy varied from case to case
and in some cases included mycophenolate mofetil or cy-
clophosphamide without adequate response as defined by
disease control with less than 0.25 mg/kg/day of prednisone
or equivalent. In each case the expected risks and benefits
and the novel nature of the regimen were explained and in-
formed consent was obtained. This report is limited to 12
patients who have completed five years of follow-up.
Rituximab and cyclophosphamide were administered as
inpatient intravenous infusions in all cases. Over eighteen
months each patient received a course of therapy consisting
of six infusions of rituximab 750 mg/M2 (up to a maximum
dose of 1 gram per infusion), followed twenty-four hours
later by cyclophosphamide at 750 mg/M2. The infusionswere given in three sets of two. Thus, a patient received
rituximab on day 0, cyclophosphamide on day 1 and then
rituximab on day 14 and cyclophosphamide on day 15 in
each set. As illustrated in Figure 1, each patient received a
set of infusions at the start of therapy, at six months, and
at eighteen months. Patients with active DPGN received
additional infusions of cyclophosphamide 750 mg/M2 at
six, ten, and fourteen weeks after the start of therapy.
Pertinent laboratory data, prednisone dosage, and SLEDAI
were recorded at the time of each initial admission for a
set of infusions and at six month intervals after the set of
infusions was completed. Five year results are presented
here, long term follow up of these patients and data col-
lection continues.
Results
Twelve patients have completed more than sixty months
of follow up. Nine were female and three male, with an
average age at diagnosis of 12.5 years and at start of ther-
apy of 16 years (range 10–28 years). Five were Caucasian,
four were Hispanic, three were Asian. Eight patients had
active DPGN; the other four did not, but were unable to
tolerate appropriate reduction in their corticosteroid dos-
age without SLE flare manifested by hypocomplemente-
mia, elevated ESR and systemic symptoms.
Combined therapy with rituximab and cyclophosph-
maide resulted in significant reduction in mean prednis-
one dosage, erythrocyte sedimentation rate, and SLEDAI
at one year which persisted through year five [see Table 1].
These changes were accompanied by significant rises in
mean C3, serum albumin, and hemoglobin. See Table 1.
Mean serum albumin rose from 3.37 gms/dl at the begin-
ning of treatment to 4.08 gms/dl at month 12 (p < 0.025)
and remained improved at 4.26 gms/dl at month 60 (P <
0.025 vs month 0). Mean serum creatinine remained stable
in the normal range throughout. CD19 levels returned to
normal in all patients by one year (six months following
the second set of rituxan and cyclophosphamide treat-
ments) and were again normal at five years of follow up.
Mean serum IgG level at the initiation of treatment was
1273 gms/dl at month 12 it was 944 gms/dl and at month
60 it was 969 gms/dl. These differences were not statisti-
cally significant. IgM levels varied widely, but the levels
were reduced with a mean at one year of follow up of
44.8 mg/dl and a mean at five years of 51.8 mg/dl. Six pa-
tients remained between 20 and 40 mg/dl at one year, but
none were lower than 20 mg/dl. At five years the IgM of
five patients remained below 40 mg/dl and one was below
20 mg/dl. Although individual patients transiently had IgM
levels below 5 mg/dl during the period of follow up, there
were no serious infections.
Four of the twelve patients remain on 10 mgs of pred-
nisone daily, the remainder less. None are Cushingoid and
all patients remained well through five years of follow-up.
Figure 1 Rituximab and cyclophosphamide dosing schedule.
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and remain ANA negative and anti-DNA negative. No
patient required mycophenolate mofetil after receiving
rituximab and cyclophosphamide. No patient experienced a
life threatening complication and there were no infusion re-
actions to rituximab. Two patients were hospitalized emer-
gently because of febrile neutropenia. Both cases responded
promptly to broad spectrum antibiotic therapy despite
negative blood, urine, and sputum cultures. Neither of the
febrile neutropenic patients was admitted to the pediatric
ICU as they were not toxic appearing or hypotensive.
Discussion
The regimen of systematically administered cyclophospha-
mide and rituximab described here minimized the need
for daily corticosteroid therapy over a sustained five years
of follow up. While compliance with the admissions for ri-
tuximab and cyclophosphamide was easily monitored and
assured, only routine efforts were made to encourage com-
pliance with the daily dosage of corticosteroids and hy-
droxychloroquine [After six years one patient developed
recurrent hematuria and a decreased C3 level which re-
solved following one additional set (two doses two weeks
apart) of rituximab and cyclophosphamide infusions and
has not recurred in eighteen months of further follow-up.
A second patient, who had become ANA negative becameTable 1 Sustained improvement at 12 and 60 months
Month 0 Month 12 Month 60
Prednisone (mg/day) 29.7 ± 24ṩ 12.7 ± 4.1# 7.0 ± 2.5*
C3 (mg/ml) 55.5 ± 27 113 ± 32** 107.5 ± 36**
ESR (mm/hr) 42.3 ± 27 17.8 ± 22* 11.8 ± 12**
Hb (gms/dl) 11.3 ± 1.8 12.1 ± 1.7# 13.2 ± 1.4#
SLEDAI 10.10 ± 5.9 1.0 ± 1.8* 0*
IgG (mgs/ml) 1272 ± 526 819 ± 200* 977 ± 505*
IgM (mgs/ml) 107 ± 52 45 ± 24* 51 ± 28#
ṩAll values represent mean ±1 Standard deviation.
#p<0.05 *p<0.005 **p<0.001.ANA positive and progressively developed additional anti-
bodies including antibodies to Sm during the sixth year.
This patient elected to be retreated with one set of rituxi-
mab and cyclophosphamide infusions following which she
no longer has antibodies to Sm, but remains ANA positive].
Intravenous cyclophosphamide is a well established alkyl-
ating agent which has long been utilized for the treatment
of childhood onset SLE [8-11]. Although it is recognized as
a potent antimetabolite the precise mechanism of its effi-
cacy in SLE is unknown [17]. While previous studies have
demonstrated that the systematic administration of intra-
venous cyclophosphamide provides significant relief for pa-
tients with SLE, significant concern remains regarding the
long term toxicity of cyclophosphamide [12,13].
Although there are many prior case reports of improve-
ment following a single treatment with cyclophosphamide
and rituximab [18], there is only one prior report of the risks
and benefits of systematically administering this therapy
which utilized a different regimen and has shorter follow-up
[19]. Rituximab has been demonstrated to efficiently elimin-
ate the circulating pool of CD20 positive B cells, but does
not eliminate the entire CD20 positive population in the
body [16]. While B cells likely play an important role in the
manifestations of SLE, the failure of controlled trials utilizing
rituximab alone indicates that CD20 positive B cells do not
act alone in the pathogenesis of SLE [15].
There was a sustained improvement with the combin-
ation of rituximab and cyclosphosphamide despite a re-
duction in the total cyclophosphamide dosage from 17
gms/M2 in the protocol previously utilized [10,11] to 6.75
gms/M2 or less (a reduction of over 60%). All of our pa-
tients were stable on a low daily dose of prednisone which
was not associated with cushingoid faces or other clinic-
ally evident adversity within one year of starting therapy.
Mycophenolate mofetil has been shown to be effective
for lupus nephritis in a number of controlled trials [14].
This regimen has not been compared to mycophenolate
mofetil. It is simply noted that satisfactory results with my-
cophenolate mofetil are dependent on compliance which is
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sert notes that mycophenolate mofetil is to be administered
twice daily despite digestive side effects reported in more
than twenty percent of patients [20].
This remains only a small number of patients. Nonethe-
less, none of the twelve patients reported have developed
significant corticosteroid related complications and none
manifest a "cushingoid" appearance. All report feeling, "like
I don't have lupus anymore." The maximum current dose
of prednisone is 10 mgs/day. In contrast to patients receiv-
ing seventeen doses of cyclophosphamide at 1 gm/M2 and
hence a total dose of 17 gms/M2 over three years, these pa-
tients received at most 6.75 gms/M2 of cyclophosphamide
over eighteen months. Similar results have been obtained
for the patients subsequently receiving this regimen, but
the emphasis of this manuscript is the sustained response.
Although we have Black patients receiving this regi-
men, none have yet completed five years of follow-up.
There is concern that disease severity and medication ef-
ficacy may vary between races in patients with SLE [21].
The major advantage of this regimen was the ability to
rapidly reduce the dosage of corticosteroids without dis-
ease flare and prevent (or rapidly resolve) the development
of Cushingoid faces and other complications of corticoster-
oid therapy. All patients were compliant with the need for
hospital admissions at the specified intervals and any non-
compliance would have been immediately evident. While
patients admit to occasionally forgetting their current dos-
age of prednisone (in most cases 5 mg daily) they do not
report any resistance to this low dosage. It is uncertain
whether it in fact remains necessary [22].Competing interests
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